Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Reward processing in major depressive disorder and prediction of treatment response - Neuropharm study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Welfare consequences for people diagnosed with attention deficit hyperactivity disorder (ADHD): A matched nationwide study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. INTERACTION OF GENETIC RISK AND EARLY LIFE STRESS ON RISK FOR DEPRESSION INVESTIGATED IN A NATIONWIDE, DANISH CASE-COHORT STUDY

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABAA receptors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Major depressive disorder (MDD) is a prevalent brain disorder for which anhedonia is a core symptom, indicating aberrations in the neural processing of reward. The striatum, medial prefrontal cortex (mPFC) and anterior insula (AI) are core reward processing regions. Here we used a reward-related, card-guessing functional magnetic resonance imaging (fMRI) paradigm to assay brain responses to reward in 90 MDD individuals and 58 healthy controls. We evaluated group differences in task-responsive, reward-related striatal, mPFC, and AI reactivity and whether baseline reactivity predicted an eight-week escitalopram antidepressant treatment response in MDD individuals. Thirty-eight MDD individuals also completed the reward paradigm after treatment and we evaluated antidepressant effects on reward reactivity estimates. Multivariate statistical analysis of task-responsive striatum, mPFC and AI brain responses did not reveal statistically significant differences between MDD and HC individuals (puncorrected>0.23). Logistic regression models (five-fold cross-validation, statistical significance assessed with permutation testing) also did not support that baseline reward-related brain responses significantly predicted antidepressant treatment response (puncorrected>0.39). Finally, reward-related brain responses were not statistically significantly changed over the course of treatment (puncorrected>0.27). Our findings in a comparatively large MDD cohort do not support that these reward-related fMRI brain responses are informative biomarkers of MDD or antidepressant treatment response to escitalopram.

Original languageEnglish
JournalEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Volume44
Pages (from-to)23-33
Number of pages11
ISSN0924-977X
DOIs
Publication statusPublished - Mar 2021

    Research areas

  • Biomarker, fMRI, Longitudinal clinical trial, Major depressive disorder, Reward, Ssri

ID: 65896435